A Look At Elevance Health (ELV) Valuation After Earnings Beat EPS But Missed Revenue And Membership Declines

Elevance Health (ELV) is in focus after reporting earnings with adjusted EPS above expectations but revenue below forecasts, while also disclosing declines in Medicaid and Medicare Advantage membership.

See our latest analysis for Elevance Health.

The stock has reacted to these mixed signals with a 1-day share price return of 1.46% and a 7-day share price return of 4.45%. However, the 1-year total shareholder return of 26.83% and 3-year total shareholder return of 31.50% point to weaker longer term momentum.

If this kind of reset in expectations has you reassessing your watchlist, it could be a useful moment to scan for other healthcare names using our healthcare focused 34 healthcare AI stocks

With Elevance trading at $316.07, sitting at a discount to both analyst targets and some estimates of intrinsic value, the key question is whether this reset leaves room for upside or if the market already prices in future growth.

Most Popular Narrative: 19.1% Undervalued

According to the most followed narrative, Elevance Health’s fair value of $390.54 sits well above the last close at $316.07, which frames the current reset as a valuation gap rather than a full rerate.

As a potential growth investment, Elevance Health offers a compelling mix of undervaluation and long-term growth drivers, particularly in the Medicare Advantage and value-based care segments. While near-term risks like Medicaid enrollment declines and cost pressures pose challenges, its diversified revenue base and focus on innovation provide resilience.

Read the complete narrative.

Curious what justifies a higher fair value despite weaker recent returns and earnings pressure? The narrative leans heavily on specific assumptions around Medicare Advantage, revenue mix, and future profit margins. The tension between modest forecast growth and a higher intrinsic value is reflected in the underlying cash flow path and the profit profile built into the model.

Result: Fair Value of $390.54 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this depends on Medicaid membership pressures and persistently high medical costs not worsening to the point where current valuation assumptions start to look too optimistic.

Find out about the key risks to this Elevance Health narrative.

Next Steps

If this mix of optimism and caution has you on the fence, looking at the underlying data yourself can help firm up your view, especially around where the market might be too pessimistic or too upbeat. Take a moment to weigh those positives by reviewing the 5 key rewards.

Looking for more investment ideas?

If Elevance has you thinking more broadly about where to put fresh capital to work, this is the moment to shortlist a few high quality alternatives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com